Anixa Biosciences Valuation
| ANIX Stock | USD 3.15 0.01 0.32% |
At this time, the firm appears to be overvalued. Anixa Biosciences shows a prevailing Real Value of $2.91 per share. The current price of the firm is $3.15. Our model approximates the value of Anixa Biosciences from analyzing the firm fundamentals such as Return On Equity of -0.63, current valuation of 81.18 M, and Shares Owned By Insiders of 5.29 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Anixa Biosciences' price fluctuation is very risky at this time. Calculation of the real value of Anixa Biosciences is based on 3 months time horizon. Increasing Anixa Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Anixa Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Anixa Stock. However, Anixa Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.15 | Real 2.91 | Hype 3.15 | Naive 3.4 |
The intrinsic value of Anixa Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Anixa Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Anixa Biosciences helps investors to forecast how Anixa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Anixa Biosciences more accurately as focusing exclusively on Anixa Biosciences' fundamentals will not take into account other important factors: Anixa Biosciences Total Value Analysis
Anixa Biosciences is presently forecasted to have valuation of 81.18 M with market capitalization of 101.1 M, debt of 232 K, and cash on hands of 31.66 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Anixa Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
81.18 M | 101.1 M | 232 K | 31.66 M |
Anixa Biosciences Asset Utilization
One of the ways to look at asset utilization of Anixa is to check how much profit was generated for every dollar of assets it reports. Anixa Biosciences shows a negative utilization of assets of -0.38 percent, losing $0.003842 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Anixa Biosciences shows how discouraging it operates for each dollar spent on its assets.Anixa Biosciences Ownership Allocation
Anixa Biosciences holds a total of 32.2 Million outstanding shares. Anixa Biosciences shows 5.29 percent of its outstanding shares held by insiders and 18.3 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Anixa Biosciences Profitability Analysis
Net Loss for the year was (12.7 M) with profit before overhead, payroll, taxes, and interest of 0.About Anixa Biosciences Valuation
Our relative valuation model uses a comparative analysis of Anixa Biosciences. We calculate exposure to Anixa Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Anixa Biosciences's related companies.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Anixa Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.
Anixa Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 31.9 M |
Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.